Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615899 | 1.00 | HCAR1 (0.52) | HCAR1KMOHCAR2CES2CES1 | |
| SCHEMBL13406398 | 0.88 | HCAR1 (0.44) | HCAR1KMOHCAR2HTR7 | |
| SCHEMBL4392929 | 0.88 | KMO (0.55) | KMOHCAR2MRGPRX4TTRCREBBP | |
| SCHEMBL184302 | 0.86 | KMO (0.53) | KMOHCAR2MRGPRX4TTRCREBBP | |
| SCHEMBL30597930 | 0.83 | PARP1 (0.44) | KMOCES2CES1NPY5R | |
| SCHEMBL3244198 | 0.83 | PARP1 (0.44) | KMOCES2CES1NPY5R | |
| SCHEMBL19404230 | 0.83 | HCAR1 (0.40) | HCAR1KMOHCAR2CES2CES1 | |
| SCHEMBL13646149 | 0.82 | P2RY14 (0.45) | HCAR1 | |
| SCHEMBL13646147 | 0.82 | P2RY14 (0.45) | HCAR1 | |
| SCHEMBL24851934 | 0.79 | HSD17B10 (0.44) | NPY5RL3MBTL1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423741-B | aryl-N-aryl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3999493-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114423741-A | aryl-N-aryl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-101801931-B | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | ALMIRALL SA | 2014-05-14 | — | — | CN | disclosed |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| US-8536165-B2 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | ALMIRALL, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-2530078-A1 | THIAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2178840-B1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2011-12-14 | — | — | EP | disclosed |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-09-01 | — | — | US | disclosed |
| CN-101801931-A | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | ALMIRALL LAB | 2010-08-11 | — | — | CN | disclosed |
| CN-101346361-A | Compound (I) | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| CN-101341133-A | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | ASTRAZENECA AB (SE) | 2009-01-07 | — | — | CN | disclosed |
| US-20080312206-A1 | Chemical Compounds-149 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| CN-101128454-A | Pyridine carboxamide derivatives for use as anticancer agents | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
| EP-1831198-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006067445-A2 | CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067446-A1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312206-A1 | Chemical Compounds-149 | CSF3R, CSF1R, FLT3 | HCAR1 1466/4885KMO 2315/4885HCAR2 1917/4885 |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | HCAR1 4211/4885KMO 2210/4885HCAR2 4206/4885 |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | HCAR1 661/4885KMO 482/4885HCAR2 628/4885 |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | HCAR1 661/4885KMO 482/4885HCAR2 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.